CLEVELAND & NEW YORK--(BUSINESS WIRE)--Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine, today announced that the company will be presenting at the JMP Securities 2014 Healthcare Conference at The Westin Grand Central in New York City.
Juventas President and CEO Rahul Aras, PhD, will present an overview of the company, platform technology and its development pipeline on Tuesday, June 24, at 3 p.m. Aras’ presentation will include top-line interim data from its Phase II study evaluating safety and efficacy of JVS-100 in patients with symptomatic ischemic cardiomyopathy which was presented last month at the European Society of Cardiology-Heart Failure Congress in Athens, Greece.
The presentation will be available on the company’s website following the conference.
JVS-100, is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 promotes cardiac function and tissue repair following a heart attack through activation of the body’s natural stem-cell based regenerative repair processes. JVS-100 is the subject of active clinical programs in heart failure (HF) and critical limb ischemia (CLI). JVS-100 is the focus of an on-going Phase II blinded, randomized, placebo-controlled trial, RETRO-HF, which is currently enrolling patients similar to those enrolled in STOP-HF with delivery via coronary sinus infusion.
About Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc., headquartered in Cleveland, Ohio, is a privately held, clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to through mid-stage clinical trials for treatment of heart failure and critical limb ischemia. Investors include Triathlon Medical Venture Partners, New Science Ventures, Fletcher Spaght Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Reservoir Venture Partners, and Cleveland Clinic. The Company has also received financial support through the Ohio Third Frontier-funded Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine. For more information, please visit www.juventasinc.com.